Matinas BioPharma (MTNB) 10-Q 10 Aug 20 2020 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2020	Aug. 06, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020
Current Fiscal Year End Date	--12-31
Entity File Number	001-38022
Entity Registrant Name	MATINAS BIOPHARMA HOLDINGS, INC.
Entity Central Index Key	0001582554
Entity Tax Identification Number	46-3011414
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1545 Route 206 South
Entity Address, Address Line Two	Suite 302
Entity Address, City or Town	Bedminster
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07921
City Area Code	908
Local Phone Number	443-1860
Title of 12(b) Security	Common Stock
Trading Symbol	MTNB
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		198,873,477

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 14,903,928	$ 22,170,438
Marketable securities	53,053,709	5,604,634
Restricted cash	200,000	250,000
Prepaid expenses and other current assets	1,051,219	1,897,784
Total current assets	69,208,856	29,922,856
Non-current assets:
Leasehold improvements and equipment - net	1,639,575	1,749,259
Operating lease right-of-use assets - net	3,523,298	3,761,207
Finance lease right-of-use assets - net	75,290	116,968
In-process research and development	3,017,377	3,017,377
Goodwill	1,336,488	1,336,488
Restricted cash - security deposits	286,000	336,000
Total non-current assets	9,878,028	10,317,299
Total assets	79,086,884	40,240,155
Current liabilities:
Accounts payable	494,577	679,310
Accrued expenses	1,434,880	1,939,510
Operating lease liabilities - current	443,801	423,741
Financing lease liabilities - current	34,573	54,673
Total current liabilities	2,407,831	3,097,234
Non-current liabilities:
Deferred tax liability	341,265	341,265
Operating lease liabilities - net of current portion	3,474,739	3,695,561
Financing lease liabilities - net of current portion	38,378	54,513
Total non-current liabilities	3,854,382	4,091,339
Total liabilities	6,262,213	7,188,573
Stockholders’ equity:
Series B Convertible preferred stock, stated value $1,000 per share, 8,000 shares authorized as of June 30, 2020 and December 31, 2019; 4,552 and 4,577 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively; (liquidation preference - $4,552,000 at June 30, 2020)	3,964,034	3,985,805
Common stock par value $0.0001 per share, 500,000,000 shares authorized at June 30, 2020 and December 31, 2019; 198,873,477 and 163,156,984 issued and outstanding as of June 30, 2020 and December 31, 2019, respectively	19,886	16,315
Additional paid-in capital	164,079,847	113,427,897
Accumulated deficit	(95,716,800)	(84,377,555)
Accumulated other comprehensive income/(loss)	477,704	(880)
Total stockholders’ equity	72,824,671	33,051,582
Total liabilities and stockholders’ equity	$ 79,086,884	$ 40,240,155

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Series B Convertible Preferred stock, par value	$ 1,000	$ 1,000
Series B Convertible Preferred stock, shares authorized	8,000	8,000
Series B Convertible Preferred stock, shares issued	4,552	4,577
Series B Convertible Preferred stock, shares outstanding	4,552	4,577
Series B Convertible Preferred stock, liquidation preference value	$ 4,552,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	198,873,477	163,156,984
Common stock, shares outstanding	198,873,477	163,156,984

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue:
Contract research revenue		$ 89,812		$ 89,812
Costs and expenses:
Research and development	3,410,237	2,828,776	7,497,120	5,143,477
General and administrative	2,356,310	1,781,717	4,615,941	3,570,131
Total costs and expenses	5,766,547	4,610,493	12,113,061	8,713,608
Loss from operations	(5,766,547)	(4,520,681)	(12,113,061)	(8,623,796)
Sale of New Jersey net operating loss		1,007,082	1,073,289	1,007,082
Other income, net	156,000	168,872	383,327	221,279
Net loss	(5,610,547)	(3,344,727)	(10,656,445)	(7,395,435)
Preferred stock series A accumulated dividends		(146,786)		(293,572)
Preferred stock series B accumulated dividends	(177,092)	(115,750)	(347,792)	(234,000)
Net loss attributable to common shareholders	$ (5,787,639)	$ (3,607,263)	$ (11,004,237)	$ (7,923,007)
Net loss available for common shareholders per share - basic and diluted	$ (0.03)	$ (0.03)	$ (0.06)	$ (0.06)
Weighted average common shares outstanding - basic and diluted	197,601,500	143,104,941	194,636,326	130,306,907
Other comprehensive (loss)/income, net of tax
Net unrealized (loss)/gain on securities available-for-sale	$ (41,954)		$ 481,303
Reclassifications to net loss	(2,708)		(2,719)
Other comprehensive (loss)/income, net of tax	(44,662)		478,584
Comprehensive loss attributable to shareholders	$ (5,655,209)	$ (3,344,727)	$ (10,177,861)	$ (7,395,435)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Redeemable Convertible Preferred Stock A [Member]	Redeemable Convertible Preferred Stock B [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Dec. 31, 2018	$ 5,583,686	$ 4,196,547	$ 11,329	$ 72,294,921	$ (65,944,759)		$ 16,141,724
Balance, shares at Dec. 31, 2018	1,467,858	4,819	113,287,670
Stock-based compensation				1,451,242			1,451,242
Issuance of common stock as compensation for services			$ 12	117,240			117,252
Issuance of common stock as compensation for services, shares			122,194
Issuance of common stock in exchange for preferred stock		$ (164,588)	$ 38	164,550
Issuance of common stock in exchange for preferred stock, shares		(189)	378,000
Issuance of common stock in public offering, net of stock issuance costs ($2,315,878)			$ 2,947	30,100,360			30,103,307
Issuance of common stock in public offering, net of stock issuance costs, shares			29,471,986
Stock dividend			$ 94	472,907	(473,001)
Stock dividend, shares			946,000
Net loss					(7,395,435)		(7,395,435)
Ending balance, value at Jun. 30, 2019	$ 5,583,686	$ 4,031,959	$ 14,420	104,601,220	(73,813,195)		40,418,090
Balance, shares at Jun. 30, 2019	1,467,858	4,630	144,205,850
Beginning balance, value at Mar. 31, 2019	$ 5,583,686	$ 4,119,043	$ 14,299	103,284,125	(69,995,467)		43,005,686
Balance, shares at Mar. 31, 2019	1,467,858	4,730	142,991,442
Stock-based compensation				763,505			763,505
Issuance of common stock as compensation for services			$ 7	58,619			58,626
Issuance of common stock as compensation for services, shares			68,408
Issuance of common stock in exchange for preferred stock		$ (87,084)	$ 20	87,064
Issuance of common stock in exchange for preferred stock, shares		(100)	200,000
Stock dividend			$ 94	472,907	(473,001)
Stock dividend, shares			946,000
Stock issuance costs				(65,000)			(65,000)
Net loss					(3,344,727)		(3,344,727)
Ending balance, value at Jun. 30, 2019	$ 5,583,686	$ 4,031,959	$ 14,420	104,601,220	(73,813,195)		40,418,090
Balance, shares at Jun. 30, 2019	1,467,858	4,630	144,205,850
Beginning balance, value at Dec. 31, 2019		$ 3,985,805	$ 16,315	113,427,897	(84,377,555)	(880)	33,051,582
Balance, shares at Dec. 31, 2019		4,577	163,156,984
Stock-based compensation				2,218,530			2,218,530
Issuance of common stock as compensation for services			$ 25	188,104			188,129
Issuance of common stock as compensation for services, shares			246,987
Issuance of common stock in exchange for preferred stock		$ (21,771)	$ 5	21,766
Issuance of common stock in exchange for preferred stock, shares		(25)	50,000
Issuance of common stock in public offering, net of stock issuance costs ($3,298,790)			$ 3,226	46,700,984			46,704,210
Issuance of common stock in public offering, net of stock issuance costs, shares			32,260,000
Issuance of common stock in exchange for Options			$ 6	42,494			42,500
Issuance of common stock in exchange for Options, shares			56,517
Issuance of common stock from the exercise of Warrants			$ 172	797,409			797,581
Issuance of common stock from the exercise of Warrants, shares			1,737,389
Stock dividend			$ 137	682,663	(682,800)
Stock dividend, shares			1,365,600
Other comprehensive loss						478,584	478,584
Net loss					(10,656,445)		(10,656,445)
Ending balance, value at Jun. 30, 2020		$ 3,964,034	$ 19,886	164,079,847	(95,716,800)	477,704	72,824,671
Balance, shares at Jun. 30, 2020		4,552	198,873,477
Beginning balance, value at Mar. 31, 2020		$ 3,964,034	$ 19,719	162,520,461	(89,423,453)	522,366	77,603,127
Balance, shares at Mar. 31, 2020		4,552	197,202,938
Stock-based compensation				850,879			850,879
Issuance of common stock as compensation for services			$ 2	15,872			15,874
Issuance of common stock as compensation for services, shares			20,537
Issuance of common stock from the exercise of Warrants			$ 28	(28)
Issuance of common stock from the exercise of Warrants, shares			284,402
Stock dividend			$ 137	682,663	(682,800)
Stock dividend, shares			1,365,600
Stock issuance costs				10,000			10,000
Other comprehensive loss						(44,662)	(44,662)
Net loss					(5,610,547)		(5,610,547)
Ending balance, value at Jun. 30, 2020		$ 3,964,034	$ 19,886	$ 164,079,847	$ (95,716,800)	$ 477,704	$ 72,824,671
Balance, shares at Jun. 30, 2020		4,552	198,873,477

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Statement of Stockholders' Equity [Abstract]
Stock issuance cost	$ 3,298,790	$ 2,315,878

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (10,656,445)	$ (7,395,435)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	115,433	96,936
Stock based compensation expense	2,391,694	1,626,594
Amortization of operating lease right-of-use assets	237,909	222,320
Amortization of finance lease right-of-use assets	41,678	72,789
Changes in operating assets and liabilities:
Operating lease liabilities	(200,762)	(169,583)
Prepaid expenses and other current assets	861,530	(14,101)
Accounts payable	(184,733)	252,476
Accrued expenses and other liabilities	(439,630)	188,095
Net cash used in operating activities	(7,833,326)	(5,119,909)
Cash flows from investing activities:
Purchase of marketable securities	(67,670,491)
Proceeds from sales of marketable securities	20,700,000
Purchases of leasehold improvements and equipment	(5,749)	(332,174)
Net cash used in investing activities	(46,976,240)	(332,174)
Cash flows from financing activities:
Net proceeds from public offering of common stock	46,639,210	30,103,307
Proceeds from exercise of warrants	797,581
Proceeds from exercise of options	42,500
Payments of capital lease liability - principal	(36,235)	(42,296)
Payments of note payable		(199,842)
Net cash provided by financing activities	47,443,056	29,861,169
Net (decrease)/increase in cash, cash equivalents and restricted cash	(7,366,510)	24,409,086
Cash, cash equivalents and restricted cash at beginning of period	22,756,438	13,007,838
Cash, cash equivalents and restricted cash at end of period	15,389,928	37,416,924
Supplemental non-cash financing and investing activities:
Deferred offering costs included in accrued expenses	65,000
Unrealized gains on marketable securities	478,584
Preferred stock conversion into common stock - Series B	21,771	164,588
Cashless exercise of warrants	441,189
Unearned restricted stock grants	73,490
Stock dividends issued	682,800	473,001
Right-of-use assets obtained in exchange for liabilities		$ 4,453,028

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Description of Business	Note 1 – Description of Business Matinas BioPharma Holdings Inc. (“Holdings”) is a Delaware corporation formed in 2013. Holdings is the parent company of Matinas BioPharma, Inc. (“BioPharma”), and Matinas BioPharma Nanotechnologies, Inc. (“Nanotechnologies,” formerly known as Aquarius Biotechnologies, Inc. and together with “Holdings” and “BioPharma”, “the Company” or “we” or “our” or “us”). The Company is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products.

Liquidity and Plan of Operation

Liquidity and Plan of Operations	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Plan of Operations	Note 2 – Liquidity and Plan of Operations The Company has experienced net losses and negative cash flows from operations each period since its inception. Through June 30, 2020, the Company had an accumulated deficit of approximately $ 95.7 10.7 The Company has been engaged in developing MAT-9001, its lead product candidate, as well as its lipid nano-crystal (“LNC”) platform delivery technology and a pipeline of associated product candidates since 2011. To date, the Company has not obtained regulatory approval for any of its product candidates nor generated any revenue from product sales and the Company expects to incur significant expenses to complete development of its product candidates. The Company may never be able to obtain regulatory approval for the marketing of any of its product candidates in any indication in the United States or internationally and there can be no assurance that the Company will generate revenues or ever achieve profitability. If the Company obtains Food and Drug Administration (“FDA”) approval for one or more of its product candidates, the Company expects that its expenses will continue to increase once the Company reaches commercial launch. The Company also expects that its research and development expenses will continue to increase as it moves forward with additional clinical studies for its current product candidates and development of additional product candidates. As a result, the Company expects to continue to incur substantial losses for the foreseeable future, and that these losses will be increasing. To continue to fund operations, on January 14, 2020, the Company completed an underwritten public offering of common stock, generating gross cash proceeds of approximately $ 50.0 46.7 As of June 30, 2020, the Company had cash and cash equivalents of approximately $ 14.9 53.1 0.5

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of Holdings and its wholly owned subsidiaries, BioPharma, and Nanotechnologies. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect the operations of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The Company’s significant accounting policies are fully described in Note 3 within the Company’s Notes to Consolidated Financial Statements included in the Company’s 2019 Form 10-K. In March 2020, the World Health Organization declared COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economics, and financial markets globally, potentially leading to an economic downturn. The Company has been actively monitoring the COVID-19 pandemic and its impact globally. The financial results for the three and six months ended June 30, 2020 were not significantly impacted by COVID-19. However, the Company cannot predict the impact of the progression of the COVID-19 pandemic on future results or the Company’s ability to raise capital due to a variety of factors, including the continued good health of Company employees, the ability of suppliers to continue to operate and deliver, the ability of the Company to maintain operations, any further government and/or public actions taken in response to the pandemic and ultimately the length of the pandemic. Recently adopted accounting pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Updated (“ASU”) 2018-13, “Changes to Disclosure Requirements for Fair Value Measurements”, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim` periods within those fiscal years, beginning after December 15, 2019. The Company adopted the guidance on January 1, 2020. The adoption did not have a material impact on our condensed consolidated financial statements. In November 2018, the FASB issued ASU 2018-18, “Collaboration Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606”, to clarify when ASC 606 should be used for collaborative arrangements when the counterparty is a customer. The guidance precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from the contracts with the customers if the counterparty is not a customer for that transaction. The guidance is effective for public entities in fiscal years beginning after December 15, 2019, and interim period therein. The Company adopted the guidance on January 1, 2020. The adoption did not have a material impact on our condensed consolidated financial statements.

Cash, Cash Equivalents, Restric

Cash, Cash Equivalents, Restricted Cash and Marketable Securities	6 Months Ended
	Jun. 30, 2020
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents, Restricted Cash and Marketable Securities	Note 4 – Cash, Cash Equivalents, Restricted Cash and Marketable Securities The Company considers all highly liquid financial instruments with original maturities of three months or less when purchased to be cash and cash equivalents and all investments with maturities of greater than three months from date of purchase are classified as marketable securities. Cash and cash equivalents consisted of cash in bank checking and savings accounts and money market funds. Cash, Cash Equivalents and Restricted Cash The Company presents restricted cash with cash and cash equivalents in the Condensed Consolidated Statements of Cash Flows. Restricted cash represents funds the Company is required to set aside to cover building operating leases and other purposes. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Condensed Consolidated Balance Sheets to the total of the amounts in the Condensed Consolidated Statements of Cash Flows as of June 30, 2020, December 31, 2019, June 30, 2019 and December 31, 2018: Schedule of Cash, Cash Equivalents and Restricted Cash June 30, December 31, June 30, December 31, Cash and cash equivalents $ 14,904 $ 22,170 $ 36,831 $ 12,447 Restricted cash included in current/long term assets 486 586 586 561 Cash, cash equivalents and restricted cash in the statement of cash flows $ 15,390 $ 22,756 $ 37,417 $ 13,008 Marketable Securities The Company has classified its investments in marketable securities as available-for-sale and as a current asset. The Company’s investments in marketable securities are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Unrealized gains and losses are classified as other comprehensive income (loss) and costs are determined on a specific identification basis. Realized gains and losses from our marketable securities are recorded in other income, net. For the three and six months ended June 30, 2020, the Company recorded unrealized losses of approximately $ 42.0 481.3 no 477.7 0.9 The following tables summarizes the Company’s marketable securities as of June 30, 2020: Summary of Cash, Cash Equivalents and Marketable Securities Amortized Unrealized Unrealized Cost Gain (Loss) Fair Value U.S. Treasury Bonds $ 28,857 $ 302 $ — $ 29,159 U.S. Government Notes 16,471 135 (1 ) 16,605 Corporate Debt Securities 6,223 33 — 6,256 State and Municipal Bonds 1,025 9 — 1,034 Total marketable securities $ 52,576 $ 479 $ (1 ) $ 53,054 Maturities of debt securities classified as available-for-sale were as follows at June 30, 2020: Schedule of Maturities of Debt Securities Available-for-sale Net Carrying Fair Value Amount Due within one year $ 29,334 $ 29,471 Due after one year through five years 23,720 23,818 $ 53,054 $ 53,289 The following tables summarizes the Company’s cash, cash equivalents and marketable securities for the year ended December 31, 2019: Summary of Cash, Cash Equivalents and Marketable Securities Amortized Unrealized Unrealized Cost Gain (Loss) Fair Value Cash and cash equivalents $ 22,169 $ 1 $ — $ 22,170 U.S. Treasury Bonds $ 4,003 $ — $ (1 ) $ 4,002 Corporate Debt Securities 1,604 — (1 ) 1,603 Total marketable securities $ 5,607 $ — $ (2 ) $ 5,605 Total cash, cash equivalents and marketable securities $ 27,776 $ 1 $ (2 ) $ 27,775 Maturities of debt securities classified as available-for-sale were as follows at December 31, 2019: Schedule of Maturities of Debt Securities Available-for-sale Net Carrying Fair Value Amount Due within one year $ 5,002 $ 5,019 Due after one year through five years 603 607 $ 5,605 $ 5,626 The Company determined that the unrealized gains and (losses) are deemed to be temporary as of June 30, 2020. Unrealized gains and (losses) generally are the result of increases in the risk premiums required by market participants rather than an adverse change in cash flows for a fundamental weakness in the credit quality of the issuer or underlying assets. The Company has the ability and intent to hold these investments until maturity. The Company does not consider the investment in marketable securities to be other-than-temporarily impaired at June 30, 2020.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 5 - Fair Value Measurements The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below: ● Level 1 – Quoted prices for identical assets or liabilities in active markets. ● Level 2 – Quoted prices for identical or similar assets and liabilities in markets that are not active; or other model-derived valuations whose inputs are directly or indirectly observable or whose significant value drivers are observable. ● Level 3 – Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable and for which assumptions are used based on management estimates. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. The carrying amounts of certain cash and cash equivalents, current portion of restricted cash, accounts receivable, prepaid expenses, accounts payable, current portion of lease liability and accrued expenses approximate fair value due to the short-term nature of these instruments. A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows: Schedule of Fair Value Measurement of Assets and Liabilities Fair Value Hierarchy June 30, 2020 Total (Level 1) (Level 2) (Level 3) Assets Marketable Securities: U.S. Treasury Bonds $ 29,159 $ 29,159 $ — $ — U.S. Government Notes 16,605 — 16,605 — Corporate Debt Securities 6,256 — 6,256 — State and Municipal Bonds 1,034 — 1,034 — Total $ 53,054 $ 29,159 $ 23,895 $ — Fair Value Hierarchy December 31, 2019 Total (Level 1) (Level 2) (Level 3) Assets Cash and cash equivalents $ 22,170 $ 22,170 $ — $ — Marketable Securities: U.S. Treasury Bonds 4,002 4,002 — — Corporate Debt Securities 1,603 — 1,603 — Total $ 27,775 $ 26,172 $ 1,603 $ — Cash and cash equivalents consisted of cash in bank checking and savings accounts, money market funds and U.S. treasury bonds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices for identical assets in active markets. Marketable securities consisting of U.S. government notes, corporate debt securities and state and municipal bonds are classified as Level 2 and are valued using quoted market prices in markets that are not active.

Leasehold Improvements and Equi

Leasehold Improvements and Equipment	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Leasehold Improvements and Equipment	Note 6 – Leasehold Improvements and Equipment Leasehold improvements and equipment, summarized by major category, consist of the following as of June 30, 2020 and December 31, 2019: Schedule of Leasehold Improvements and Equipment June 30, 2020 December 31, 2019 Lab equipment $ 1,443 $ 1,437 Leasehold improvements 878 878 Total 2,321 2,315 Less: accumulated depreciation and amortization 681 566 Leasehold improvements and equipment, net $ 1,640 $ 1,749 Depreciation and amortization expense for the three and six months ended June 30, 2020 was approximately $ 57.8 thousand and approximately $ 115.4 thousand, respectively, and for the three and six months ended June 30, 2019 was approximately $ 47.9 thousand and approximately $ 96.9 thousand, respectively.

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
Accrued Expenses	Note 7 – Accrued Expenses Accrued Expenses, summarized by major category, as of June 30, 2020 and December 31, 2019 consist of the following: Schedule of Accrued Expenses June 30, 2020 December 31, 2019 Payroll and incentives $ 534 $ 978 General and administrative expenses 334 428 Research and development expenses 367 421 Deferred revenue 200 100 Other - 13 Total $ 1,435 $ 1,940

Leases

Leases	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Leases	Note 8 – Leases The Company has various lease agreements with original terms of up to 10 years, including leases of office space, a laboratory and manufacturing facility, and various equipment. Some leases include purchase, termination or extension options for one or more years These options are included in the lease term when it is reasonably certain that the option will be exercised. The assets and liabilities from operating and finance leases are recognized at the lease commencement date based on the present value of remaining lease payments over the lease term using the Company’s incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet. The Company’s operating leases do not provide an implicit rate that can readily be determined. Therefore, the Company uses a discount rate based on its incremental borrowing rate, which is determined using the average of borrowing rates explicitly stated in the Company’s finance leases. The Company incurred lease expense for its operating leases of approximately $ 203.4 406.8 The Company incurred interest expense on its finance leases of approximately $ 1.7 4.0 3.1 6.5 18.8 41.7 36.4 72.8 The following table presents information about the amount and timing of liabilities arising from the Company’s operating and finance leases as of June 30, 2020: Schedule of Maturity of Operating and Finance Leases Liabilities Maturity of Lease Liabilities Operating Lease Liabilities Finance Lease Liabilities Remainder of 2020 $ 383 $ 21 2021 685 34 2022 645 19 2023 677 2 2024 710 - Thereafter $ 2,203 $ - Total undiscounted operating lease payments $ 5,303 76 Less: Imputed interest 1,384 $ 3 Present value of operating lease liabilities $ 3,919 $ 73 Weighted average remaining lease term in years 7.1 2.1 Weighted average discount rate 8.4 8.1 The following table presents information about the amount and timing of liabilities arising from the Company’s operating and finance leases as of December 31, 2019: Schedule of Weighted Average Lease Term and Discount Rate Maturity of Lease Liabilities Operating Lease Liabilities Finance Lease Liabilities 2020 $ 753 $ 60 2021 685 34 2022 645 19 2023 677 2 2024 710 - Thereafter $ 2,203 $ - Total undiscounted operating lease payments $ 5,673 115 Less: Imputed interest 1,554 $ 6 Present value of operating lease liabilities $ 4,119 $ 109 Weighted average remaining lease term in years 7.5 2.2 Weighted average discount rate 8.4% 7.8

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 9 – Income Taxes Sale of net operating losses (NOLs) The Company recognized $ 0 1.1 1.0

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Stockholders’ Equity	Note 10 – Stockholders’ Equity Common Stock On January 14, 2020, the Company closed on an underwritten public offering of 32.3 1.55 50.0 46.7 4.8 Preferred Stock Series B Preferred Stock In connection with a public offering of Series B Preferred Stock, on June 19, 2018, the Company filed the Series B Certificate of Designation with the Secretary of the State of Delaware to designate the preferences, rights and limitations of the Series B Preferred Stock. Pursuant to the Series B Certificate of Designation, the Company designated 8,000 4,552 4,577 Dividends Subject to certain ownership limitations, holders of the Series B Preferred Stock received or are entitled to receive dividends payable in the Company’s common stock as follows: (i) a number of shares of common stock equal to 10% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2019, (ii) a number of shares of common stock equal to 15% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2020 and (iii) a number of shares of common stock equal to 20% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2021. 1,365,600 946,000 Warrants The Company has issued two types of warrants: (i) investor warrants and (ii) placement agent warrants. All warrants are exercisable immediately upon issuance and have a five-year term. The warrants may be exercised at any time in whole or in part upon payment of the applicable exercise price until expiration. No fractional shares will be issued upon the exercise of the warrants. The exercise price and the number of shares purchasable upon the exercise of the investor warrants are subject to adjustment upon the occurrence of certain events, which include stock dividends, stock splits, combinations and reclassifications of the Company’s capital stock or other similar changes to the equity structure of the Company. As of June 30, 2020, the Company had outstanding warrants to purchase an aggregate of 1,327,810 0.50 0.75 Summary of Shareholders Equity Warrants Outstanding Shares Outstanding at December 31, 2018 5,799 Issued - Exercised (402 ) Tendered - Expired - Outstanding at December 31, 2019 5,397 * Outstanding at December 31, 2019 5,397 Issued - Exercised (2,576 )** Tendered - Expired (1,493 ) Outstanding at June 30, 2020 1,328 *** * Weighted average exercise price for outstanding warrants is $ 0.62 ** Converted into approximately 1,737.4 *** Weighted average exercise price for outstanding warrants is $ 0.55 Basic and diluted net loss per common share During the three and six months ended June 30, 2020 and 2019, diluted earnings per common share is the same as basic earnings per common share because, as the Company incurred a net loss during each period presented, the potentially dilutive securities from the assumed exercise of all outstanding stock options, warrants and conversion of preferred stock, would have an anti-dilutive effect. The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common shareholders because including them would have been anti-dilutive for the three and six months ended June 30, 2020 and 2019: Schedule of Antidilutive Securities As of June 30, 2020 2019 Stock options 22,317 16,625 Preferred Stock and accrued dividend upon conversion 9,104 26,287 Warrants 1,328 5,799 Total 32,749 48,711

Accumulated Other Comprehensive

Accumulated Other Comprehensive (Loss)/Income	6 Months Ended
	Jun. 30, 2020
Accumulated Other Comprehensive Lossincome
Accumulated Other Comprehensive (Loss)/Income	Note 11 – Accumulated Other Comprehensive (Loss)/Income The following table summarizes the changes in accumulated other comprehensive (loss)/income by components during the six months ended June 30, 2020: Schedule of Components of Accumulated Other Comprehensive Income/(Loss) Net Unrealized (Losses)/Gains on Available-for-Sale Securities Accumulated Other Comprehensive (Loss)/Gain Balance, December 31, 2019 $ (1 ) $ (1 ) Unrealized gain on securities available-for-sale 482 482 Reclassifications to net loss (3 ) (3 ) Net current period other comprehensive income 479 479 Balance, June 30, 2020 $ 478 $ 478 The amounts reclassified to net income for realized gains and losses on available-for-sale securities are recorded as part of other income, net, in our Condensed Consolidated Statements of Operations and Comprehensive Loss. There were no accumulated other comprehensive (losses)/gains during the six months ended June 30, 2019 and all components of accumulated other comprehensive (losses)/gains are net of tax. Realized gains and losses and declines in value judged to be other-than-temporary are included in the determination of net loss and are included in other income, net.

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock-based Compensation	Note 12 – Stock-based Compensation The Company’s Amended and Restated 2013 Equity Compensation Plan (the “Plan”) provides for the granting of incentive stock options, nonqualified stock options, restricted stock units, performance units, and stock purchase rights. There were no significant modifications to the Plan during the six months ended June 30, 2020 and 2019. With the approval of the Board of Directors and a majority of shareholders, effective May 8, 2014, the Plan was amended and restated. The amendment provides for an automatic increase in the number of shares of common stock available for issuance under the Plan each January, commencing January 1, 2015 4 The following table contains information about the Company’s stock plan at June 30, 2020: Schedule of Equity Compensation Plan by Arrangements Awards Reserved for Issuance Awards Issued & Exercised Awards Available for Grant 2013 Equity Compensation Plan (in thousands) 28,948 * 24,836 ** 4,112 * Increased by 6,526 4 ** Includes both stock grants and option grants The Company recognized stock-based compensation expense (options and restricted share grants) in its condensed consolidated statements of operations as follows: Schedule of Recognized Stock-Based Compensation Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Research and Development $ 358 $ 350 $ 1,180 $ 649 General and Administrative 587 472 1,212 977 Total $ 945 $ 822 $ 2,392 $ 1,626 During the six months ended June 30, 2020, the Company modified the exercise terms of certain vested stock options resulting in additional stock-based compensation expense of approximately $ 432.8 The exercise terms were due to expire on February 9, 2020 two years As of June 30, 2020, total compensation costs related to unvested awards not yet recognized was approximately $ 9.7 million and the weighted-average periods over which the awards are expected to be recognized was 3.1 years. Stock Options The following table summarizes the activity for Company’ stock options for the three months ended June 30, 2020 (in thousands): Schedule of Stock Option Activity Stock Options Outstanding at January 1, 2020 17,529 Granted 5,250 Exercised (100 )* Forfeited (72 ) Cancelled - Expired (290 ) Outstanding at June 30, 2020 22,317 * Converted into approximately 56.5 Restricted Stock Awards During the six months ended June 30, 2020 and 2019, the Company granted restricted stock awards for 247 122 93.2 173.2 58.7 175.4 73.5 200,000 0.3

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Event	Note 13 – Subsequent Event On July 2, 2020, the Company filed a Registration Statement on Form S-3 for the sale of its common stock, preferred stock, warrants, debt securities and subscription rights having an aggregate offering price of up to $ 200,000,000 Also on July 2, 2020, the Company entered into an At-The-Market Sales Agreement (the “Sales Agreement”) with BTIG, LLC (“BTIG”), pursuant to which the Company may offer and sell, from time to time, through BTIG, as sales agent and/or principal, shares of its common stock having an aggregate offering price of up to $ 50,000,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of presentation and principles of consolidation	Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of Holdings and its wholly owned subsidiaries, BioPharma, and Nanotechnologies. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect the operations of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The Company’s significant accounting policies are fully described in Note 3 within the Company’s Notes to Consolidated Financial Statements included in the Company’s 2019 Form 10-K. In March 2020, the World Health Organization declared COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economics, and financial markets globally, potentially leading to an economic downturn. The Company has been actively monitoring the COVID-19 pandemic and its impact globally. The financial results for the three and six months ended June 30, 2020 were not significantly impacted by COVID-19. However, the Company cannot predict the impact of the progression of the COVID-19 pandemic on future results or the Company’s ability to raise capital due to a variety of factors, including the continued good health of Company employees, the ability of suppliers to continue to operate and deliver, the ability of the Company to maintain operations, any further government and/or public actions taken in response to the pandemic and ultimately the length of the pandemic.
Recently adopted accounting pronouncements	Recently adopted accounting pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Updated (“ASU”) 2018-13, “Changes to Disclosure Requirements for Fair Value Measurements”, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim` periods within those fiscal years, beginning after December 15, 2019. The Company adopted the guidance on January 1, 2020. The adoption did not have a material impact on our condensed consolidated financial statements. In November 2018, the FASB issued ASU 2018-18, “Collaboration Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606”, to clarify when ASC 606 should be used for collaborative arrangements when the counterparty is a customer. The guidance precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from the contracts with the customers if the counterparty is not a customer for that transaction. The guidance is effective for public entities in fiscal years beginning after December 15, 2019, and interim period therein. The Company adopted the guidance on January 1, 2020. The adoption did not have a material impact on our condensed consolidated financial statements.

Cash, Cash Equivalents, Restr_2

Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2020
Cash and Cash Equivalents [Abstract]
Schedule of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Condensed Consolidated Balance Sheets to the total of the amounts in the Condensed Consolidated Statements of Cash Flows as of June 30, 2020, December 31, 2019, June 30, 2019 and December 31, 2018: Schedule of Cash, Cash Equivalents and Restricted Cash June 30, December 31, June 30, December 31, Cash and cash equivalents $ 14,904 $ 22,170 $ 36,831 $ 12,447 Restricted cash included in current/long term assets 486 586 586 561 Cash, cash equivalents and restricted cash in the statement of cash flows $ 15,390 $ 22,756 $ 37,417 $ 13,008
Summary of Cash, Cash Equivalents and Marketable Securities	The following tables summarizes the Company’s marketable securities as of June 30, 2020: Summary of Cash, Cash Equivalents and Marketable Securities Amortized Unrealized Unrealized Cost Gain (Loss) Fair Value U.S. Treasury Bonds $ 28,857 $ 302 $ — $ 29,159 U.S. Government Notes 16,471 135 (1 ) 16,605 Corporate Debt Securities 6,223 33 — 6,256 State and Municipal Bonds 1,025 9 — 1,034 Total marketable securities $ 52,576 $ 479 $ (1 ) $ 53,054
Schedule of Maturities of Debt Securities Available-for-sale	Maturities of debt securities classified as available-for-sale were as follows at June 30, 2020: Schedule of Maturities of Debt Securities Available-for-sale Net Carrying Fair Value Amount Due within one year $ 29,334 $ 29,471 Due after one year through five years 23,720 23,818 $ 53,054 $ 53,289
Summary of Cash, Cash Equivalents and Marketable Securities	The following tables summarizes the Company’s cash, cash equivalents and marketable securities for the year ended December 31, 2019: Summary of Cash, Cash Equivalents and Marketable Securities Amortized Unrealized Unrealized Cost Gain (Loss) Fair Value Cash and cash equivalents $ 22,169 $ 1 $ — $ 22,170 U.S. Treasury Bonds $ 4,003 $ — $ (1 ) $ 4,002 Corporate Debt Securities 1,604 — (1 ) 1,603 Total marketable securities $ 5,607 $ — $ (2 ) $ 5,605 Total cash, cash equivalents and marketable securities $ 27,776 $ 1 $ (2 ) $ 27,775
Schedule of Maturities of Debt Securities Available-for-sale	Maturities of debt securities classified as available-for-sale were as follows at December 31, 2019: Schedule of Maturities of Debt Securities Available-for-sale Net Carrying Fair Value Amount Due within one year $ 5,002 $ 5,019 Due after one year through five years 603 607 $ 5,605 $ 5,626

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value Measurement of Assets and Liabilities	A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows: Schedule of Fair Value Measurement of Assets and Liabilities Fair Value Hierarchy June 30, 2020 Total (Level 1) (Level 2) (Level 3) Assets Marketable Securities: U.S. Treasury Bonds $ 29,159 $ 29,159 $ — $ — U.S. Government Notes 16,605 — 16,605 — Corporate Debt Securities 6,256 — 6,256 — State and Municipal Bonds 1,034 — 1,034 — Total $ 53,054 $ 29,159 $ 23,895 $ — Fair Value Hierarchy December 31, 2019 Total (Level 1) (Level 2) (Level 3) Assets Cash and cash equivalents $ 22,170 $ 22,170 $ — $ — Marketable Securities: U.S. Treasury Bonds 4,002 4,002 — — Corporate Debt Securities 1,603 — 1,603 — Total $ 27,775 $ 26,172 $ 1,603 $ —

Leasehold Improvements and Eq_2

Leasehold Improvements and Equipment (Tables)	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Schedule of Leasehold Improvements and Equipment	Leasehold improvements and equipment, summarized by major category, consist of the following as of June 30, 2020 and December 31, 2019: Schedule of Leasehold Improvements and Equipment June 30, 2020 December 31, 2019 Lab equipment $ 1,443 $ 1,437 Leasehold improvements 878 878 Total 2,321 2,315 Less: accumulated depreciation and amortization 681 566 Leasehold improvements and equipment, net $ 1,640 $ 1,749

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued Expenses, summarized by major category, as of June 30, 2020 and December 31, 2019 consist of the following: Schedule of Accrued Expenses June 30, 2020 December 31, 2019 Payroll and incentives $ 534 $ 978 General and administrative expenses 334 428 Research and development expenses 367 421 Deferred revenue 200 100 Other - 13 Total $ 1,435 $ 1,940

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Schedule of Maturity of Operating and Finance Leases Liabilities	The following table presents information about the amount and timing of liabilities arising from the Company’s operating and finance leases as of June 30, 2020: Schedule of Maturity of Operating and Finance Leases Liabilities Maturity of Lease Liabilities Operating Lease Liabilities Finance Lease Liabilities Remainder of 2020 $ 383 $ 21 2021 685 34 2022 645 19 2023 677 2 2024 710 - Thereafter $ 2,203 $ - Total undiscounted operating lease payments $ 5,303 76 Less: Imputed interest 1,384 $ 3 Present value of operating lease liabilities $ 3,919 $ 73 Weighted average remaining lease term in years 7.1 2.1 Weighted average discount rate 8.4 8.1
Schedule of Weighted Average Lease Term and Discount Rate	The following table presents information about the amount and timing of liabilities arising from the Company’s operating and finance leases as of December 31, 2019: Schedule of Weighted Average Lease Term and Discount Rate Maturity of Lease Liabilities Operating Lease Liabilities Finance Lease Liabilities 2020 $ 753 $ 60 2021 685 34 2022 645 19 2023 677 2 2024 710 - Thereafter $ 2,203 $ - Total undiscounted operating lease payments $ 5,673 115 Less: Imputed interest 1,554 $ 6 Present value of operating lease liabilities $ 4,119 $ 109 Weighted average remaining lease term in years 7.5 2.2 Weighted average discount rate 8.4% 7.8

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Summary of Shareholders Equity Warrants Outstanding	Summary of Shareholders Equity Warrants Outstanding Shares Outstanding at December 31, 2018 5,799 Issued - Exercised (402 ) Tendered - Expired - Outstanding at December 31, 2019 5,397 * Outstanding at December 31, 2019 5,397 Issued - Exercised (2,576 )** Tendered - Expired (1,493 ) Outstanding at June 30, 2020 1,328 *** * Weighted average exercise price for outstanding warrants is $ 0.62 ** Converted into approximately 1,737.4 *** Weighted average exercise price for outstanding warrants is $ 0.55
Schedule of Antidilutive Securities	Schedule of Antidilutive Securities As of June 30, 2020 2019 Stock options 22,317 16,625 Preferred Stock and accrued dividend upon conversion 9,104 26,287 Warrants 1,328 5,799 Total 32,749 48,711

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive (Loss)/Income (Tables)	6 Months Ended
	Jun. 30, 2020
Accumulated Other Comprehensive Lossincome
Schedule of Components of Accumulated Other Comprehensive Income/(Loss)	The following table summarizes the changes in accumulated other comprehensive (loss)/income by components during the six months ended June 30, 2020: Schedule of Components of Accumulated Other Comprehensive Income/(Loss) Net Unrealized (Losses)/Gains on Available-for-Sale Securities Accumulated Other Comprehensive (Loss)/Gain Balance, December 31, 2019 $ (1 ) $ (1 ) Unrealized gain on securities available-for-sale 482 482 Reclassifications to net loss (3 ) (3 ) Net current period other comprehensive income 479 479 Balance, June 30, 2020 $ 478 $ 478

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Equity Compensation Plan by Arrangements	The following table contains information about the Company’s stock plan at June 30, 2020: Schedule of Equity Compensation Plan by Arrangements Awards Reserved for Issuance Awards Issued & Exercised Awards Available for Grant 2013 Equity Compensation Plan (in thousands) 28,948 * 24,836 ** 4,112 * Increased by 6,526 4 ** Includes both stock grants and option grants
Schedule of Recognized Stock-Based Compensation	The Company recognized stock-based compensation expense (options and restricted share grants) in its condensed consolidated statements of operations as follows: Schedule of Recognized Stock-Based Compensation Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Research and Development $ 358 $ 350 $ 1,180 $ 649 General and Administrative 587 472 1,212 977 Total $ 945 $ 822 $ 2,392 $ 1,626
Schedule of Stock Option Activity	The following table summarizes the activity for Company’ stock options for the three months ended June 30, 2020 (in thousands): Schedule of Stock Option Activity Stock Options Outstanding at January 1, 2020 17,529 Granted 5,250 Exercised (100 )* Forfeited (72 ) Cancelled - Expired (290 ) Outstanding at June 30, 2020 22,317 * Converted into approximately 56.5

Liquidity and Plan of Operati_2

Liquidity and Plan of Operations (Details Narrative) - USD ($)	Jan. 14, 2020	Jan. 14, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Subsidiary, Sale of Stock [Line Items]
Accumulated deficit			$ 95,700,000
Net loss			10,700,000
Proceeds from public offering		$ 50,000,000	46,639,210	$ 30,103,307
Cash and cash equivalents			14,903,928		$ 22,170,438
Marketable securities			53,053,709		$ 5,604,634
Restricted cash			$ 500,000
Underwritten Public Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from public offering of common stock, gross	$ 50,000,000
Proceeds from public offering	$ 46,700,000

Schedule of Cash, Cash Equivale

Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 14,904	$ 22,170	$ 36,831	$ 12,447
Restricted cash included in current/long term assets	486	586	586	561
Cash, cash equivalents and restricted cash in the statement of cash flows	$ 15,390	$ 22,756	$ 37,417	$ 13,008

Summary of Cash, Cash Equivalen

Summary of Cash, Cash Equivalents and Marketable Securities (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Total marketable securities, Amortized Cost	$ 52,576	$ 5,607
Total marketable securities, Unrealized Gain	479
Total marketable securities, Unrealized (Loss)	(1)	(2)
Total marketable securities, Fair Value	53,054	5,605
Cash and cash equivalents, Amortized Cost		22,169
Cash and cash equivalents, Unrealized Gain		1
Cash and cash equivalents, Unrealized (Loss)
Cash and cash equivalents, Fair Value		22,170
Total cash, cash equivalents and marketable securities, Amortized Cost		27,776
Total cash, cash equivalents and marketable securities, Unrealized Gain		1
Total cash, cash equivalents and marketable securities, Unrealized (Loss)		(2)
Total cash, cash equivalents and marketable securities, Fair Value		27,775
U.S. Treasury Bonds [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Total marketable securities, Amortized Cost	28,857	4,003
Total marketable securities, Unrealized Gain	302
Total marketable securities, Unrealized (Loss)		(1)
Total marketable securities, Fair Value	29,159	4,002
U.S. Government Notes [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Total marketable securities, Amortized Cost	16,471
Total marketable securities, Unrealized Gain	135
Total marketable securities, Unrealized (Loss)	(1)
Total marketable securities, Fair Value	16,605
Corporate Debt Securities [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Total marketable securities, Amortized Cost	6,223	1,604
Total marketable securities, Unrealized Gain	33
Total marketable securities, Unrealized (Loss)		(1)
Total marketable securities, Fair Value	6,256	$ 1,603
State And Municipal Bonds [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Total marketable securities, Amortized Cost	1,025
Total marketable securities, Unrealized Gain	9
Total marketable securities, Unrealized (Loss)
Total marketable securities, Fair Value	$ 1,034

Schedule of Maturities of Debt

Schedule of Maturities of Debt Securities Available-for-sale (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Cash and Cash Equivalents [Abstract]
Fair Value, Due within one year	$ 29,334	$ 5,002
Net Carrying Amount, Due within one year	29,471	5,019
Fair Value, Due after one year through five years	23,720	603
Net Carrying Amount, Due after one year through five years	23,818	607
Fair Value, Debt Securities, Available-for-sale, Maturity	53,054	5,605
Net Carrying Amount, Debt Securities, Available-for-sale, Maturity	$ 53,289	$ 5,626

Cash, Cash Equivalents, Restr_3

Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Cash and Cash Equivalents [Abstract]
Marketable securities, unrealized loss	$ 42,000		$ 42,000
Marketable securities, unrealized gain	481,300		481,300
Marketable securities, unrealized gain loss		$ 0		$ 0
Accumulated unrealized gain	$ 477,700		$ 477,700
Accumulated unrealized loss					$ 900

Schedule of Fair Value Measurem

Schedule of Fair Value Measurement of Assets and Liabilities (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	$ 53,054
Cash and cash equivalents		$ 22,170
Total		27,775
Fair Value, Inputs, Level 1 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	29,159
Cash and cash equivalents		22,170
Total		26,172
Fair Value, Inputs, Level 2 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	23,895
Cash and cash equivalents
Total		1,603
Fair Value, Inputs, Level 3 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
Cash and cash equivalents
Total
U.S. Treasury Bonds [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	29,159	4,002
U.S. Treasury Bonds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	29,159	4,002
U.S. Treasury Bonds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
U.S. Treasury Bonds [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
U.S. Government Notes [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	16,605
U.S. Government Notes [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
U.S. Government Notes [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	16,605
U.S. Government Notes [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
Corporate Debt Securities [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	6,256	1,603
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	6,256	1,603
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
State And Municipal Bonds [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	1,034
State And Municipal Bonds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
State And Municipal Bonds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	1,034
State And Municipal Bonds [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Marketable Securities

Schedule of Leasehold Improveme

Schedule of Leasehold Improvements and Equipment (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Total	$ 2,321	$ 2,315
Less: accumulated depreciation and amortization	681	566
Leasehold improvements and equipment, net	1,640	1,749
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	1,443	1,437
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total	$ 878	$ 878

Leasehold Improvements and Eq_3

Leasehold Improvements and Equipment (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Depreciation	$ 57,800	$ 47,900	$ 115,400	$ 96,900

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Payroll and incentives	$ 534	$ 978
General and administrative expenses	334	428
Research and development expenses	367	421
Deferred revenue	200	100
Other		13
Total	$ 1,435	$ 1,940

Schedule of Maturity of Operati

Schedule of Maturity of Operating and Finance Leases Liabilities (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Operating Lease [Member]
Lessee, Lease, Description [Line Items]
Operating Lease Liabilities, Remainder of 2020	$ 383	$ 753
Operating Lease Liabilities, 2021	685	685
Operating Lease Liabilities, 2022	645	645
Operating Lease Liabilities, 2023	677	677
Operating Lease Liabilities, 2024	710	710
Thereafter	2,203	2,203
Total undiscounted operating lease payments	5,303	5,673
Less: Imputed interest	1,384	1,554
Present value of operating lease liabilities	$ 3,919	$ 4,119
Weighted average remaining lease term in years	7 years 1 month 6 days	7 years 6 months
Weighted average discount rate	8.40%	8.40%
Finance Lease [Member]
Lessee, Lease, Description [Line Items]
Finance Lease Liabilities, Remainder of 2020	$ 21	$ 60
Finance Lease Liabilities, 2021	34	34
Finance Lease Liabilities, 2022	19	19
Finance Lease Liabilities, 2023	2	2
Finance Lease Liabilities, 2024
Thereafter
Total undiscounted finance lease payments	76	115
Less: Imputed interest	3	6
Present value of finance lease liabilities	$ 73	$ 109
Weighted average remaining lease term in years	2 years 1 month 6 days	2 years 2 months 12 days
Weighted average discount rate	8.10%	7.80%

Schedule of Weighted Average Le

Schedule of Weighted Average Lease Term and Discount Rate (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Operating Lease [Member]
Lessee, Lease, Description [Line Items]
Operating Lease Liabilities, 2020	$ 383	$ 753
Operating Lease Liabilities, 2021	685	685
Operating Lease Liabilities, 2022	645	645
Operating Lease Liabilities, 2023	677	677
Operating Lease Liabilities, 2024	710	710
Thereafter	2,203	2,203
Total undiscounted operating lease payments	5,303	5,673
Less: Imputed interest	1,384	1,554
Present value of operating lease liabilities	$ 3,919	$ 4,119
Weighted average remaining lease term in years	7 years 1 month 6 days	7 years 6 months
Weighted average discount rate	8.40%	8.40%
Finance Lease [Member]
Lessee, Lease, Description [Line Items]
Finance Lease Liabilities, 2020	$ 21	$ 60
Finance Lease Liabilities, 2021	34	34
Finance Lease Liabilities, 2022	19	19
Finance Lease Liabilities, 2023	2	2
Finance Lease Liabilities, 2024
Thereafter
Total undiscounted finance lease payments	76	115
Less: Imputed interest	3	6
Present value of finance lease liabilities	$ 73	$ 109
Weighted average remaining lease term in years	2 years 1 month 6 days	2 years 2 months 12 days
Weighted average discount rate	8.10%	7.80%

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Lessee, Operating Lease, Term of Contract	10 years		10 years
Lessee, Operating Lease, Option to Extend			Some leases include purchase, termination or extension options for one or more years
Lease expense	$ 203,400	$ 406,800	$ 203,400	$ 406,800
Finance lease, interest expense	1,700	3,100	4,000	6,500
Finance lease, amortization expense	$ 18,800	$ 36,400	$ 41,678	$ 72,789

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Sale of net operating losses	$ 0	$ 1,000,000	$ 1,100,000	$ 1,000,000

Summary of Shareholders Equity

Summary of Shareholders Equity Warrants Outstanding (Details) - $ / shares	6 Months Ended		12 Months Ended
	Jun. 30, 2020		Dec. 31, 2019
Equity [Abstract]
Shares Outstanding, beginning	5,397	[1]	5,799
Shares Issued
Shares Exercised	(2,576)	[2]	(402)
Shares Tendered
Shares Expired	(1,493)
Shares Outstanding, ending	1,328	[3]	5,397	[1]
Weighted average of exercise price for outstanding warrants	$ 0.55		$ 0.62
Number of warrant common stock converted	1,737,400
[1]	Weighted average exercise price for outstanding warrants is $ 0.62
[2]	Converted into approximately 1,737.4
[3]	Weighted average exercise price for outstanding warrants is $ 0.55

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive earnings per share, amount	32,749	48,711
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive earnings per share, amount	22,317	16,625
Preferred Stock and Accrued Dividend Upon Conversion [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive earnings per share, amount	9,104	26,287
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive earnings per share, amount	1,328	5,799

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	Jan. 14, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net proceeds from public offering of common stock	$ 50,000,000			$ 46,639,210	$ 30,103,307
Series B Convertible Preferred stock shares designated		8,000		8,000		8,000
Series B Convertible Preferred stock, shares outstanding		4,552		4,552		4,577
Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Dividend payable description				Subject to certain ownership limitations, holders of the Series B Preferred Stock received or are entitled to receive dividends payable in the Company’s common stock as follows: (i) a number of shares of common stock equal to 10% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2019, (ii) a number of shares of common stock equal to 15% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2020 and (iii) a number of shares of common stock equal to 20% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2021.
Stock dividend, shares				1,365,600	946,000
Merger Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net proceeds from public offering of common stock	$ 46,700,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of underwritten public offering of common stock	32,300,000			32,260,000
Purchase price	$ 1.55
Stock dividend, shares		1,365,600	946,000	1,365,600	946,000
Common Stock [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Options to purchase an additional shares of common stock	4,800,000
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrant to purchase of common stock		1,327,810		1,327,810
Warrant [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of warrant or right, exercise price of warrants or rights		$ 0.75		$ 0.75
Warrant [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of warrant or right, exercise price of warrants or rights		$ 0.50		$ 0.50

Schedule of Components of Accum

Schedule of Components of Accumulated Other Comprehensive Income/(Loss) (Details)	6 Months Ended
	Jun. 30, 2020USD ($)
Accumulated Other Comprehensive Lossincome
Net Unrealized (Losses)/Gains on Available-for-Sale Securities, Beginning Balance	$ (1)
Accumulated Other Comprehensive (Loss)/Gain, Beginning Balance	(1)
Net Unrealized (Losses)/Gains on Available-for-Sale Securities, Unrealized gain on securities available-for-sale	482
Accumulated Other Comprehensive (Loss)/Gain, Unrealized gain on securities available-for-sale	482
Net Unrealized (Losses)/Gains on Available-for-Sale Securities, Reclassifications to net income	(3)
Accumulated Other Comprehensive (Loss)/Gain, Reclassifications to net income	(3)
Net Unrealized (Losses)/Gains on Available-for-Sale Securities, Other comprehensive gain	479
Accumulated Other Comprehensive (Loss)/Gain, Other comprehensive gain	479
Net Unrealized (Losses)/Gains on Available-for-Sale Securities, Ending Balance	478
Net Unrealized (Losses)/Gains on Available-for-Sale Securities, Ending Balance	$ 478

Schedule of Equity Compensation

Schedule of Equity Compensation Plan by Arrangements (Details) - shares		May 08, 2014	Jun. 30, 2020	Jan. 02, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increased shares of common stock outstanding				6,526,000
Percentage for common stock outstanding		4.00%	4.00%
Two Thousand Thirteen Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards Reserved for Issuance	[1]		28,948
Awards Issued & Exercised	[2]		24,836
Awards Available for Grant			4,112
[1]	Increased by 6,526 4
[2]	Includes both stock grants and option grants

Schedule of Recognized Stock-Ba

Schedule of Recognized Stock-Based Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 945	$ 822	$ 2,392	$ 1,626
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	358	350	1,180	649
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 587	$ 472	$ 1,212	$ 977

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2020shares
Share-based Payment Arrangement [Abstract]
Number of Options, Outstanding at Beginning	17,529,000
Number of Options, Granted	5,250,000
Number of Options, Exercised	(100,000)	[1]
Number of Options, Forfeited	(72,000)
Number of Options, Cancelled
Number of Options, Expired	(290,000)
Number of Options, Outstanding at Ending	22,317,000
Common stock, shares converted	56,500
[1]	Converted into approximately 56.5

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) - USD ($)	May 08, 2014	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment award increase of shares offering date	January 1, 2015
Share-based payment award, percentage of outstanding stock maximum	4.00%			4.00%
Number of option vested		432,800		432,800
Option term				The exercise terms were due to expire on February 9, 2020 but were extended for an additional two years and will be cancelled if not exercised on or before February 9, 2022.
Expiration date				Feb. 9, 2020
Option vested period				2 years
Unrecognized share-based compensation		$ 9,700,000		$ 9,700,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition				3 years 1 month 6 days
Number of restricted stock awards granted				247,000	122,000
General and administrative expense		93,200	$ 58,700	$ 173,200	$ 175,400
Non-vested restricted stock grants weighted-average period				3 months 18 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized share-based compensation		$ 73,500		$ 73,500
Unrecognized share-based compensation, shares		200,000		200,000

Subsequent Event (Details Narra

Subsequent Event (Details Narrative) - USD ($)	Jul. 02, 2020	Jan. 14, 2020	Jun. 30, 2020	Jun. 30, 2019
Subsequent Event [Line Items]
Net proceeds from public offering of common stock		$ 50,000,000	$ 46,639,210	$ 30,103,307
Subsequent Event [Member]
Subsequent Event [Line Items]
Net proceeds from public offering of common stock	$ 200,000,000
Subsequent Event [Member] | Market Sales Agreement [Member] | Lab Equipment [Member]
Subsequent Event [Line Items]
Net proceeds from public offering of common stock	$ 50,000,000